Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.
3 reports, 1 independent
Updated Sep 11
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup, Morgan Stanley, and TD Cowen have raised their price targets and upgraded ratings for Royalty Pharma, with filings made public via the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Royalty Pharma
biopharmaceutical company based in New York City
-
Citigroup
American investment bank and financial services corporation
-
Morgan Stanley
U.S. investment bank
-
TD Cowen
American investment bank
Related events
- MarketBeat published average ratings and price targets for Kalaris Therapeutics, while Citigroup reaffirmed an outperform rating and TD Cowen initiated coverage with a buy rating.
- TD Cowen, Stephens, Citigroup, and MarketBeat provided new analyst ratings and coverage for Covenant Logistics Group, Inc.
- Citigroup boosted its price target and gave a buy rating for Carrier Global Corporation.
- Citigroup and Truist Financial issued buy ratings and increased price targets for Cisco.
- Citigroup and Royal Bank of Canada raised price targets and ratings for a company, with MarketBeat aggregating the financial data.